• Skip to main content

Some venture capital investors are betting big on cannabis

Published: May 2, 2017, 3:37 pm • Updated: May 2, 2017, 3:37 pm

By Marisa Kendall, Bay Area News Group

Silicon Valley investors are known for pouring money into risky bets like flying cars and asteroid mining. Now, a handful are diving into one of the few industries that makes most of their peers squeamish — pot.

As the marijuana industry soars, with New Frontier Data predicting legal pot sales will balloon to more than $24 billion by 2025, a handful of venture capitalists are climbing on board — albeit cautiously. Those putting money into the industry say it’s a rare chance to stake an early claim in a lucrative market with little competition from other investors. But they’re keeping one eye on President Donald Trump’s administration, watching for signs of a federal crackdown that could derail the burgeoning industry.

“It’s a completely untapped market with huge opportunity,” said Tusk Ventures Founder and CEO Bradley Tusk, an investor in San Francisco-based marijuana delivery darling Eaze.

For Tusk Ventures, a VC firm that specializes in helping startups like Uber and FanDuel navigate complex regulatory landscapes, the controversial marijuana industry seemed like a natural fit. The firm is considering a second investment in the space.

And it’s not alone. DCM Ventures, a 21-year-old VC firm with an office on Sand Hill Road, also invested in Eaze, as did Fresh VC and the Winklevoss twins — the brothers who made headlines by claiming they came up with the idea for Facebook. Other investors dabbling in pot companies include prestigious Mountain View-based startup accelerator Y Combinator, Peter Thiel’s Founders Fund and New York City-based Lerer Hippeau Ventures — which also backs big names like Soylent, which makes meal-replacement drinks and bars popular among Silicon Valley techies, and Venmo, a mobile payments platform.

Industry insiders say there’s been a slow uptick in interest. Investors have poured nearly $30 million into marijuana-tech startups — companies that sell marijuana-related technology or use tech to sell cannabis products — so far this year, according to PitchBook Data. That means 2017 is on track to beat last year’s total of $49 million. But much of that money is coming from niche firms created exclusively to fund cannabis-related businesses, such as Phyto Partners and Poseidon Asset Management.

Despite the marijuana industry’s massive potential, interest from Sand Hill Road has amounted to more of a trickle than a flood. Though California voters approved recreational marijuana use last November, and lawmakers are working on crafting regulations to allow sales to start next year, the plant remains illegal on the federal level. That leaves most VCs unwilling to venture into the industry. Many venture capital firms are forbidden from entering the space by agreements with their limited partners — the pension funds and other institutions that supply the VCs’ investment capital.

“This is a no-go area for traditional venture funds, at least for now,” said Venky Ganesan, chairman of the board of the National Venture Capital Association and managing director of Menlo Ventures.

While mainstream VCs hesitate, a crop of investment firms specializing in marijuana have sprung up to fill the void. Groups like Los Angeles-based Casa Verde Capital, backed by rapper Snoop Dogg; and Gateway, an Oakland-based incubator for cannabis startups, can take much of the credit for keeping the marijuana tech industry afloat.

Pranav Sood, whose Oakland-based startup Trellis sells inventory management software to cannabis growers and distributors, recently turned to the industry’s niche investors after striking out with mainstream VCs.

“It quickly became apparent that more traditional VCs are not really getting into this space,” he said. “That’s when we kind of shifted focus as well. It was a pretty quick lesson learned.”

Trellis is closing its first round of funding, which will bring in $2 million from a group of investors led by Casa Verde. Sood said investor sentiment toward the marijuana industry has been volatile — spiking as support grew for legalized recreational marijuana, dropping with Trump’s arrival in office, and picking back up recently.

“Honestly, it’s been a little bit of a roller coaster,” he said. “On any given day, you don’t know how an investor’s going to feel.”

Brian Sheng, a partner at Fresh VC, said his firm was drawn to Eaze partly because the startup never actually touches marijuana — Eaze only provides the online platform that connects dispensaries with customers. That cuts down on the risk, Sheng said.

Private equity also is expanding into marijuana. MedMen, a Los Angeles-based firm that manages companies in the cannabis space, launched its first marijuana-focused private equity fund last summer, which now controls almost $100 million in assets. The firm also held its first investment conference last month, drawing more than 300 people interested in putting their money into the marijuana industry. So far the cash going into these types of funds has mostly been from wealthy individuals and families, MedMen Co-Chairman Chris Leavy said, but pension funds, endowments, foundations and other institutional investors are starting to show interest.

“Access to capital for this industry is slowly improving,” Leavy said. “Wherever you look, you can see signs that the investor interest is broadening.”

This story was first published on TheCannifornian.com

Learn how biocontrols work to beat the bad bugs that wreck cannabis crops

Published: May 2, 2017, 2:54 pm • Updated: May 2, 2017, 2:54 pm

By John Chandler, The Cannabist Staff

Even the best-managed commercial cannabis cultivations must continually worry about, and defend against, pest infestation.

When pests get out of control, it puts more than your high-value cannabis crop at risk. You face the loss of your reputation, as well as potential government intervention, batch failure and product recall. In fact, the cost of remediation for an outbreak is often five or more times greater than preventative care. With a proactive Integrated Pest Management (IPM) program, you can effectively keep pests at bay to avoid economic loss.

As state and federal laws surrounding production of cannabis continue to evolve, low-toxicity approaches such as biocontrols can help ensure both regulatory compliance and safety for consumers and employees. Unlike traditional pesticides, most biocontrols are exempt from federal registration with the Environmental Protection Agency. Biocontrols are largely regulated by state departments of agriculture, so confirm with local regulatory authorities to ensure compliance.

But what’s the best strategy for incorporating a biocontrol program? Is it right for your facility?

What are biocontrols?

Biological controls, also known as biocontrols, are beneficial living organisms such as predatory insects, mites, nematodes and microbes such as certain types of fungi and bacteria that can be applied as a method of controlling pests. When properly utilized, they help with common problems including fungus gnats, root aphids, spider mites, russet mites, whiteflies and thrips.

Beneficials are predators, parasites and/or pathogens that take out pests in various ways:

• Predatory mites that eat other mites and insects, such as A. californicus, A. swirskii and A. andersoni, can be applied preventatively to the crop via breeder sachets — self-contained packages placed within the plant canopy that contain a food source for the predators, allowing them to breed and emerge in a “timed-release” way, minimizing application labor.

• Parasitoid wasps such as Aphidius sp., Encarsia formosa and Eretmocerus eremicus turn aphids and whiteflies into mummies.

• Chrysopa carnea, green lacewing larva, are voracious consumers of many soft-bodied insects at various stages of life, including spider mite eggs.

• Parasitic nematodes (Steinernema sp. and Heterorhabditis sp.) and entomopathogenic fungi (Beauveria bassiana, Metarhizium anisopliae and Paecilomyces fumosoroseus) invade the bodies of many insect pests, using their host as a breeding ground.

Large-scale horticultural facilities regularly rely on biocontrols to manage or eliminate pest populations. During a recent visit to a 100-acre field-grown strawberry operation in California, I witnessed a farmer applying Phytoseiulus persimilis — a predatory mite — to mitigate a spider mite population. Spider mites are ever-present in commercial agriculture and cannabis, but the use of predatory foliar mites can limit the spread of these pest mites.

When should you use beneficials?

Biocontrols are not the answer to every problem. They certainly won’t bail you out of web-covered colas in week seven. They must be used proactively. The idea is to maintain low levels of beneficials to watch over the crop, constantly searching for pests. If you have breeder sachets of A. californicus in your plants and a government inspector inadvertently brings in a couple spider mites while on a site visit, you won’t even know, because the californicus will take them out before they become a problem. The same goes for other pests. Once a large population of pests is established, beneficials can’t keep up with exploding populations. A knock-down spray treatment is necessary in these cases, with mild pesticides that won’t carry a residual effect that would prevent the next release of beneficials from taking hold. Horticultural oils are a good choice for this sort of knock down.

urban-gro-Californicus-breeder-sachetsThis breeder sachet contains A. californicus predatory mites. (Courtesy of Urban-Gro)

A couple of my favorites

The parasitic nematode, a nearly microscopic worm called Steinernema feltiae, is one of the most effective ways to handle those pesky, persistent fungus gnats. Steinernema, applied through irrigation or a “sprench” (spray/drench) actively search for fungus gnat larvae. They enter the pest larvae through a natural opening and reproduce inside, effectively killing the larvae. Steinernema, like many biocontrols, need to be applied fairly frequently. They can be a very cost-effective solution. As an added benefit, they also infect thrips larvae, so you have an added layer of protection from those pests.

Phytoseiulus persimilis, commonly known as persimilis, is a voracious predatory mite that will consume all life stages of spider mites. They can eat up to 20 eggs or five adults a day. Thanks to their appetite and rapid reproduction, they are known to completely eradicate mite populations. I like using them in the plant clone stage to ensure you are going into early flower without spider mites. They can also be used to suppress small outbreaks. Many large cannabis and tomato greenhouses receive weekly shipments to spread in specific areas that are getting out of control.

What went wrong?

I’ve heard a number of growers say they haven’t had luck with bios in the past. This can be due to a number of reasons. Incorporating a biocontrol program can be tricky, but they certainly can work with some attention to detail.

First, since bios are normally overnight-shipped from manufacturers, make sure they have arrived alive. When you have received a shipment, carefully inspect the organisms with a hand lens. Reputable beneficial manufacturers should replace them if you let them know of problems immediately upon delivery. A package of beneficial nematodes should smell earthy when fresh, not like decaying matter. Use a microscope to ensure viability of nematodes.

Second, if there have been toxic and persistent pesticides used in an indoor facility in the past months or even years, residue may still be lingering that would prevent the beneficials from establishing and effectively controlling pests. Specifically, miticides like abamectin (Avid) are highly persistent indoors. Check with your supplier for specific concerns about pesticides.

Third, you should start small and incorporate bios into a small portion of your facility. Carry a hand lens and monitor the effectiveness of your releases. Beneficials can be very hard to see cruising in the foliage, but if you dedicate a couple hours, you should be able to find them.

No need to avoid beneficials

I’ve seen no ill effects from introducing biocontrols. The beneficial insects released into production facilities are not attracted to the resinous, sticky buds of flowering marijuana plants; they’re attracted solely to pests. In the five years I’ve been managing and consulting for large-scale cannabis facilities, I’ve never gotten a report of any crop damage or failed microbial testing due to beneficials. I’ve also never gotten a report of someone finding beneficials in their finished product.

I’ve also heard many growers say they avoid implementing a biocontrol program due to perceived cost of bios and concern over application details. It is not necessarily more expensive to use biocontrols when factors like employee time, chemical cost and limited working hours (due to restricted entry intervals) are considered.

Many traditional greenhouse growers choose to incorporate biocontrols into their IPM programs because they are in fact good for their bottom line. Also, the value added to chemical-free crops may be extremely critical for some markets. Incidentally, the best bud I’ve smoke recently came from a facility utilizing bios.

Good IPM decisions and implementation of biocontrol programs often require product expertise. When experts collaborate with growers, there do not have to be pest-caused crop losses. Just remember that IPM plans for large-scale cannabis growers should be designed to meet state-specific needs for regulatory compliance.

Do you have a success story using biocontrols effectively in your own commercial facility? Please send me a message via the email in my bio below — I’m intrigued with the variety of unique approaches, and I’m happy to follow up in this forum with an update on biologicals.

John Chandler farmed more than 300 acres of certified organic produce for many years before he became a professional cannabis producer in Colorado in 2012. He has a horticulture degree from Texas A&M University and is a certified crop adviser…

Last New England state to decriminalize weed takes first step

Published: May 2, 2017, 1:31 pm • Updated: May 2, 2017, 1:31 pm

By The Associated Press

CONCORD, N.H. — Marijuana decriminalization is one step closer to passage in New Hampshire after lawmakers worked out a compromise that police chiefs can stomach.

An amendment by Republican Sen. Jeb Bradley would remove criminal penalties for possessing up to three-quarters of an ounce of marijuana, less than the original bill’s one ounce threshold. New Hampshire is the only New England state without decriminalization.

Members of the Senate Judiciary Committee gave initial approval to the bill Tuesday, sending it to the Senate floor with a positive recommendation. The Senate has typically resisted decriminalization bills.

The bill reduces the possible penalty for possessing small amounts of pot from a misdemeanor to a violation with a maximum penalty of up to $300. It also decriminalizes possession of up to 5 grams of hashish.

Scotts Miracle-Gro homing in on ‘big vision’ for hydroponics as state-legal cannabis grows

Published: May 2, 2017, 12:43 pm • Updated: May 2, 2017, 12:45 pm

By Alicia Wallace, The Cannabist Staff

The wet weather may be dampening sales for Scotts Miracle-Gro’s core lawn-and-garden business, but the company has its sights on the grow lights at the end of the tunnel.

CEO Jim Hagedorn on Tuesday underscored his firm’s “big vision” for hydroponics and the seriousness with which Scotts is approaching that sector as more states adopt medical and recreational marijuana laws.

“We have no sense of humor about that” potential maturation of the hydroponics business, Hagedorn told analysts during the company’s fiscal second-quarter earnings call. “This is a space we understand really well. We’re growing-people.”

And if other deep-pocketed companies or private equity want to step in, Scotts is ready to step up, he said.

“We intend to succeed in that space,” Hagedorn said. “I would say to anyone who wants to rumble with us, come on, let’s do this.”

The Marysville, Ohio-based Scotts has emerged as one of the biggest players in traditional business to publicly establish a foothold in the ancillary wings of the cannabis industry. The company has acquired several sector-leading firms across hydroponics areas such as lighting, soil and nutrients, and wrapped those into its Hawthorne Gardening Co. subsidiary.

Scotts has a few more acquisitions waiting in the pipeline, but some are taking longer than expected, Hagedorn said, attributing any delays to the logistics of these firms being smaller, family-owned businesses.

“We expect to complete most of these deals by the end of the year,” he said.

The buyouts inked to-date have resulted in revenue growth that has “significantly exceeded expectations.”

Hawthorne’s total sales were not disclosed in Scotts’ earnings report and initial related public filings made Tuesday. However, the subsidiary’s growth spurt was evident in the company’s top line for the second quarter and six month fiscal-year-to-date, which ended on April 1, 2017:

U.S. consumer sales dropped 7 percent to $962.5 million for the quarter, and fell 6 percent to $1.09 billion over the past six months; consumer sales in Europe fell 8 percent in both the quarter and fiscal six months to $105.3 million and $129.7 million, respectively.  The “Other” category — consisting of lawn-and-garden business outside the U.S. and Europe, a supply agreement with Israel chemicals, and the hydroponics and urban gardening businesses — saw a 50 percent sales spike in the quarter to $135.7 million and a 59 percent jump for the  fiscal year-to-date to $232.6 million.

Most of those growth spikes came from acquisitions, Hagedorn said, noting that Hawthorne also is experiencing strong, organic growth.

Each of the hydroponics businesses within Hawthorne — including General Hydroponics, Gavita and AeroGrow — had double-digit sales growth in the quarter, bringing the hydroponics portfolio’s quarterly sales growth to 22 percent and fiscal year-to-date sales growth to 13 percent, Hagedorn said.

“The overall landscape continues to look positive for Hawthorne,” he said.

Separately, Scotts on Tuesday announced plans to sell its European and Australian business operations, a deal that would result in 95 percent of the firm’s sales and profits being derived from the United States.

The transaction, which could result in $150 million in cash proceeds to Scotts, signals another significant aspect of the transition for the “quintessential American company” as it looks to counter a slowdown in its core business, Hagedorn said.

“We love our core business, but I think we view it as somewhat mature and slow-growing,” he said.

The ventures into areas such as hydroponics allow Scotts to start “buying growth” in categories with greater potential.

As that hydroponics market evolves from the recreational grower to the professional grower, Scotts has that lineage and technical sophistication that could serve the needs of both smaller and larger growers alike, Hagedorn said.

“I’m very comfortable where we’re going with this,” he said.

Alicia Wallace joined The Cannabist in July 2016, covering national marijuana policy and business. She contributes to the Denver Post’s beer industry coverage. In her 13 years as a business news reporter, her coverage has spanned the economy, Sports…

The endocannabinoid system explained

Published: May 2, 2017, 12:29 pm • Updated: May 2, 2017, 12:30 pm

By Melissa Sherrard, Civilized

Whether our reasons have been medical, spiritual, or recreational, we’ve been using cannabis as a species for thousands of years. However, it wasn’t until recently that we’ve started to understand how marijuana affects us in so many ways. Here we briefly describe what is known as the endogenous cannabinoid system (or endocannabinoid system) that is present in almost all vertebrates.

Discovered piece by piece since the 1960s, the endocannabinoid system (ECS) works to promote homeostasis, which in a biological sense is stable internal environment despite external fluctuations and circumstances. The ECS is composed of a huge network of receptors throughout much of the body (including the brain and other organs, connective tissues, glands, and the central and peripheral nervous systems) and even though these receptors do different things the aim of achieving homeostasis at every level of the body is always the same.



The ECS does this through a vast system of receptors (the two most well-known are CB1 and CB2) on the surface of cell membranes throughout the body, endocannabinoids created by the body on demand (the two most-studied are anandamide and 2-arachidonoylglycerol), and metabolic enzymes called fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) that break down cannabinoids once used. CB1 receptors are predominantly found in the central nervous system, glands, and organs 
while CB2 receptors are mainly found in tissues associated with the immune system. However, it’s believed that the ECS has more receptors than any other system in the human body, and many tissues have both CB1 and CB2 receptors, each providing its own specific action depending on the site.



This account by no means describes all the known nuances of the ECS and the effects it has shown in many physiological functions. The identification of the ECS led us to understand that our bodies harbor a vast biological system made specifically for interactions with active chemical compounds ourselves (endocannabinoids) and similar compounds we find in cannabis plants (phytocannabinoids). To end, it’s no secret that cannabis does unpredictable things to the human body, so there’s no guarantee that activating one’s ECS with marijuana will produce the desired effect, but as our understanding of the way various cannabis strains affect our ECS we can make use of them in the best way possible.

This story was first published on Civilized.Life

Uruguay opens registry for world’s first government-run marijuana market

Published: May 2, 2017, 9:27 am • Updated: May 2, 2017, 9:27 am

By The Associated Press

BUENOS AIRES, Argentina — Uruguay is beginning to register people who want to legally buy marijuana at pharmacies as part of the world’s first government-regulated national marketplace for pot.

Authorities announced the registry’s launch Tuesday.

Uruguay legalized the cultivation and sale of marijuana in 2013.

The law allows the growing of pot by licensed individuals, the formation of growers and users clubs and the sale by pharmacies. Registered users will be able to buy 40 grams a month. Only Uruguayan citizens and legal residents over the age of 18 can register.

The government has yet to announce when the pharmacies will begin selling pot.

It will cost about $1.30 per gram. Companies that won the government bid to grow it will charge about $.90. The rest will be split between pharmacies and the government.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Interim pages omitted …
  • Page 46
  • Go to Next Page »
Access Politics Health Higher Learning
Licensed Producers Dispensaries Clinics

Cultivate Change © 2026 WeedHub | info@weedhub.ca